At a glance
We are COMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD). We are currently conducting a randomised controlled phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are also assessing the potential of psilocybin therapy in the treatment of other mental health and neurological conditions. We are headquartered in London, UK, with offices in New York, US.
Our vision is a world of mental wellbeing.